e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Malignant mesothelioma, are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio prognostic indicator parameters as reliable?
Seda Tural Önür (Istanbul, Turkey), Seda Tural Onur, Sinem Sokucu, Levent Dalar, Kaan Kara, Songul Buyukkale, Sedat Altin
Source:
International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Session:
Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Session type:
Thematic Poster Session
Number:
4324
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Seda Tural Önür (Istanbul, Turkey), Seda Tural Onur, Sinem Sokucu, Levent Dalar, Kaan Kara, Songul Buyukkale, Sedat Altin. Malignant mesothelioma, are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio prognostic indicator parameters as reliable?. Eur Respir J 2015; 46: Suppl. 59, 4324
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Asbestosis
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis
Diagnosis and staging of malignant pleural mesothelioma
Related content which might interest you:
Exploring the neutrophil/lymphocyte and platelet/lymphocyte ratios as biomarkers for lung cancer development
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
The prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with non-small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker?
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Prognostic value of haematological markers such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in small cell lung cancer.
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Pulmonary originated sepsis: Can N/L ratio be used as follow-up marker?
Source: International Congress 2016 – Infections, sepsis, and pulmonary embolism
Year: 2016
Is neutrophil/lymphocyte ratio at the time of diagnosis a valuable prognostic factor in non-small cell lung cancer?
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Evaluating the utility of mesothelin in diagnosing mesothelioma
Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases
Year: 2013
Changes in neutrophil-lymphocyte and platelet-lymphocyte ratios and clinical outcomes in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias
Year: 2018
Potential role of total antioxidant status ratio in differential diagnosis of pleural effusion
Source: Annual Congress 2013 –Interventional pulmonology and pleural diseases
Year: 2013
Prognostic value of neutrophil-to-lymphocyte ratio in hospitalized patients with COVID-19
Source: Virtual Congress 2021 – COVID - 19
Year: 2021
Neutrophil to lymphocyte ratio (NLR) as a predictor of poor prognosis in advanced non-small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Evaluation of pleural fluid total protein, albumin, globulin levels and albumin/globulin ratios in the differential diagnosis of pleural effusions
Source: International Congress 2016 – From pleura to bronchi: new insights
Year: 2016
Is YKL-40 a prognostic marker in sarcoidosis?
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
BNP can be an all-cause mortality predictor in sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
The protein DJ-1 in malignant pleural effusions due to lung cancer: Levels and correlations with oxidative stress biomarkers
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
An elevated neutrophil lymphocyte ratio is a poor prognostic marker in all categories of pleural effusions
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Is comorbidity a good prognostic factor for malignant pleural mesothelioma?
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Thymic tumours: update on classification and prognostic factors
Source: Annual Congress 2012 - Diagnosis and management of thymic malignancies: an update
Year: 2012
Neutrophil/lymphocyte ratio as a prognostic marker for curative-intent surgery in non-small cell lung cancer
Source: International Congress 2015 – Surgery and lung cancer: results and complications
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept